Jefferies analyst Martin Comtesse maintained a Buy rating on Redcare Pharmacy today and set a price target of €170.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Martin Comtesse has given his Buy rating due to a combination of factors that highlight Redcare Pharmacy’s strong financial performance and future potential. The company reported a significant increase in profitability, with a notable 15% beat on adjusted EBITDA, driven by a reduction in marketing expenses. This resulted in a Q2 margin of 2.6%, exceeding the full-year target range of 2.0-2.5%.
Additionally, the reaffirmation of the 2025 guidance indicates a positive outlook, with expectations of renewed momentum in prescription sales in the coming months. The lifting of the prescription bonus ban in Germany is anticipated to boost marketing efforts, further enhancing sales in the third quarter and beyond. These factors collectively support the Buy rating, reflecting confidence in the company’s ability to sustain growth and improve margins.
According to TipRanks, Comtesse is an analyst with an average return of -0.5% and a 42.69% success rate. Comtesse covers the Industrials sector, focusing on stocks such as Bechtle Aktiengesellschaft, INFICON Holding AG, and Friedrich Vorwerk Group SE.